Akeso.
Chinese Biopharmaceutical Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 26
What's happening
Earlier this month
-
Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.Well supported8 reports
-
Akeso is expanding its clinical trials into the US through a collaboration with the Icahn School of Medicine at Mount Sinai.Some support1 report
One to three months ago
-
Janus Henderson is backing biotech reverse mergers while dueling drug data emerges between involved companies.Some support2 reports
-
Akeso, a Zhongshan-based company in Guangdong, reported that its drug outperformed MSD's Keytruda in trials, showcasing the rise of Chinese biotech.Some support5 reports
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Akeso this week
News at the entities that move Akeso most-
MSD OperationalZusduri, a product of Urogen Pharma, is gaining market traction against competitors like MSD's Keytruda and Ferring's Adstiladrin.Moves Akeso
-
FDA StructuralThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves Akeso
-
Summit Therapeutics StructuralMarketBeat provided stock average ratings while Leerink Partners upgraded and Barclays raised its price objective for Summit Therapeutics.Moves Akeso
-
Icahn School of Medicine at Mount Sinai OperationalNCI awarded a grant to a consortium involving Rutgers, Mount Sinai, and Stanford for cancer research.Moves Akeso
-
Merck OperationalMerck forged a strategic alliance with R-Pharm on November 1, 2026.Moves Akeso
-
AstraZeneca OperationalAnalyst reports are driving stock market sentiment for Ballard Power Systems, AstraZeneca, Amgen, and Amazon.Moves Akeso
Connections
The 23 strongest of 26, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Xia Yu Structural
Xia Yu is the founder, chairwoman, and CEO of Akeso.
-
Summit Therapeutics Structural
Summit Therapeutics relies on Akeso's core IP and engineering expertise for the co-development and commercialization of ivonescimab.
-
MSD Operational
Akeso and MSD are direct competitors whose drugs are being evaluated against each other in clinical trials.
-
Yu Xia Structural
Yu Xia serves as the President and CEO of Akeso.
-
Michelle Xia Structural
Michelle Xia holds a leadership role, leading Akeso's global clinical development.
-
Merck Operational
The companies are actively competing in the market, evidenced by the emergence of conflicting clinical data regarding their respective drug pipelines.
-
FDA Structural
The FDA formally monitors and regulates Akeso's drug development process for U.S. market approval.
-
Icahn School of Medicine at Mount Sinai Operational
Akeso and Icahn School of Medicine at Mount Sinai are actively collaborating on clinical trials.
Show all 23 connections
-
Summit Operational
Akeso and Summit are actively collaborating on the joint development and study of the drug ivonescimab.
-
Innovent Biologics Operational
Both companies are identified as key players and competitors within the Chinese biopharma sector.
-
Janus Henderson Transactional
Janus Henderson is backing biotech reverse mergers, indicating an investment relationship with Akeso.
-
AstraZeneca Operational
Akeso's drug successfully outperformed AstraZeneca's Imfinzi in head-to-head clinical trials, indicating direct market competition.
-
Guangdong Shared context
Akeso is a company located in Guangdong Province, benefiting from its regional biopharma ecosystem.
-
Chicago Shared context
The company was relevant to the industry conference (ASCO) held in the city.
-
China Daily Structural
Akeso utilizes China Daily as a platform to report and disseminate information regarding its successes and market presence.
-
Sanofi Mentioned together
The entities are mentioned within a broader context discussing the growth trends of Chinese versus Western companies.
-
Pfizer Shared context
The companies operate within a market context where Chinese companies are observed to be growing faster than Western counterparts.
-
Zhongshan Shared context
Akeso is a company headquartered in the city of Zhongshan.
-
China Shared context
Akeso conducted a Phase III study within China.
-
European Society for Medical Oncology Shared context
Akeso presented clinical trial results at the European Society for Medical Oncology conference.
-
Madrid Shared context
Akeso presented results at a congress held in Madrid.
-
Eli Lilly and Company Mentioned together
Akeso and Eli Lilly are mentioned in the context of regional growth trends comparing Chinese and Western companies.
-
DeepSeek Mentioned together
Akeso and DeepSeek are grouped together in the context of comparing their recent growth trajectories.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
1 eventJuly 2026
1 eventShow 1 earlier month
June 2026
2 events- Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.
- A collection of industry news reported on June 6th, including Akeso's success reported by China Daily, the general trend of Chinese companies outpacing Western counterparts, and the ASCO meeting held in Chicago.